Biotechnology major Biocon on Friday said the Bengaluru-based plant of Biocon Biologics has received EU GMP approval for a biosimilar product.
Biocon Biologics' facility has received a certificate of GMP compliance for Bevacizumab from the representative European inspection authority -- Health Products Regulatory Authority (HPRA), Ireland.
Bevacizumab is indicated for the treatment of various types of cancers and a specific eye disease.
"This approval reflects Biocon Biologics compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients in the EU," a company spokesperson said in a statement.
This (B3) facility, which is one of India's largest monoclonal antibodies (mAbs) manufacturing facilities, had received the EU GMP Certification for manufacturing biosimilar Trastuzumab last year, the spokesperson said.
Biocon Biologics is a subsidiary of Biocon Ltd.
Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%
Shreehas Tambe elevated as MD & CEO of Biocon Biologics effective Monday
Serum Institute to pump in additional $150 mn in Biocon Biologics
Biocon Biologics completes acquisition of Viatris' global biosimilars biz
Biocon Biologics elevates Shreehas Tambe as managing director, CEO
Star Health Insurance earns net profit of Rs 102 cr in March quarter
InGovern recommends 'for' vote for Reliance-JioFS spinoff proposal
After Reliance-Warner deal, JioCinema pricing and local content in focus
UltraTech Q4 net profit falls 36% to Rs 1,670 cr, revenue up 17.7%
Singapore's Wilmar quarterly profit falls 24% on Adani JV stake dilution
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)